Merck Highlights Early Tiespectus Data - Poll - MDSpire

Merck Highlights Early Tiespectus Data

At the ASRS meeting in Montreal, Baruch D. Kuppermann, MD, PhD, presented BRVO findings from the phase 1/2a RIOJA program evaluating the investigational VEGF/Tie2 bispecific.

  • By

  • Jim Gallagher, senior managing editor

  • July 15, 2026

  • 3 min

Share

Original Source(s)

Merck Highlights Early Tiespectus Data

  • by Jim Gallagher, senior managing editor

  • July 15, 2026

Related Content

The Promise of Gene Therapy

With phase 3 topline data for sura-vec expected later this year, Arshad M. Khanani, MD, FASRS, reflects on how gene therapy could transform long-term treatment for nAMD.

Efficacy of intradermal acupuncture for ocular surface diseases secondary to refractory peripheral facial palsy: a randomized controlled trial study protocol

Differential tear metabolomics in blepharokeratoconjunctivitis and herpes simplex keratitis: potential biomarkers for clinical differentiation